{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T15:36:22Z","timestamp":1794065782956,"version":"4.8.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"am","delay-in-days":297,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","award":["18-004992"],"award-info":[{"award-number":["18-004992"]}],"id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","award":["21-003184"],"award-info":[{"award-number":["21-003184"]}],"id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23AI143882"],"award-info":[{"award-number":["K23AI143882"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ijantimicag.2025.107586","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T22:56:28Z","timestamp":1754434588000},"page":"107586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Piperacillin\/tazobactam clearance predicted by non-creatinine based estimates of GFR in critically ill adults"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0996-1487","authenticated-orcid":false,"given":"Erin F.","family":"Barreto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5645-0014","authenticated-orcid":false,"given":"Jack","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0338-7784","authenticated-orcid":false,"given":"Andrew D.","family":"Rule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8783-0191","authenticated-orcid":false,"given":"Kristin C.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Fogelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2886-8835","authenticated-orcid":false,"given":"Johar","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Jannetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun P.","family":"Athreya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc H.","family":"Scheetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ognjen","family":"Gajic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina G.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Ausman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie A.","family":"Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Wessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2025.107586_bib0001","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s00134-015-3822-1","article-title":"A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISe investigators","volume":"41","author":"Angus","year":"2015","journal-title":"Intensive Care Medicine"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0002","first-page":"1163","article-title":"Surviving sepsis campaign","author":"Evans","year":"2021","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0003","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1517\/17425255.2013.799137","article-title":"Drug absorption, distribution, metabolism and excretion considerations in critically ill adults","volume":"9","author":"Roberts","year":"2013","journal-title":"Exp Opin Drug Metabol Toxicol"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-015-0750-y","article-title":"Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?","volume":"19","author":"Udy","year":"2015","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0005","doi-asserted-by":"crossref","DOI":"10.1007\/s00134-024-07459-8","article-title":"Failure of target attainment for beta-lactam antibiotics and ciprofloxacin in acute brain-injured intensive care patients","author":"Ergezen","year":"2024","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/phar.2766","article-title":"Adequacy of cefepime concentrations in the early phase of critical illness: a case for precision pharmacotherapy","author":"Barreto","year":"2023","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0007","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijantimicag.2014.12.017","article-title":"Augmented renal clearance, low \u03b2-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study","volume":"45","author":"Huttner","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0008","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u00df-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2024.9779","article-title":"Continuous vs intermittent \u03b2-lactam antibiotic infusions in critically ill patients with sepsis: the BLING III randomized clinical trial","author":"Dulhunty","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1017\/ice.2015.226","article-title":"Indications and types of antibiotic agents used in 6 Acute care hospitals, 2009-2010: a pragmatic retrospective observational study","volume":"37","author":"Kelesidis","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0011","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1164\/rccm.201609-1848OC","article-title":"The timing of early antibiotics and hospital mortality in sepsis","volume":"196","author":"Liu","year":"2017","journal-title":"Am J Respiratory Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0012","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40262-021-01013-1","article-title":"Piperacillin-tazobactam in Intensive care units: a review of population pharmacokinetic analyses","volume":"60","author":"El-Haffaf","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0013","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1128\/AAC.01657-16","article-title":"Pharmacokinetics of piperacillin in critically ill Australian indigenous patients with severe sepsis","volume":"60","author":"Tsai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0014","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ijantimicag.2014.01.028","article-title":"Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course","volume":"43","author":"Carlier","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0015","unstructured":"Pfizer Inc. Piperacillin\/tazobactam full prescribing information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/050684s88s89s90_050750s37s38s39lbl.pdf (accessed June 22, 2023)."},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0016","first-page":"35","article-title":"Cystatin C: a primer for pharmacists","volume":"8","author":"Teaford","year":"2020","journal-title":"Pharmacy (Basel, Switzerland)"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0017","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2019.10.025","article-title":"Creatinine: from physiology to clinical application","volume":"72","author":"Kashani","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0018","first-page":"1","article-title":"Measured and estimated glomerular filtration rate in the ICU","author":"Sangla","year":"2020","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0019","article-title":"A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease","author":"Delgado","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0020","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.mayocp.2018.08.002","article-title":"Prediction of the renal elimination of drugs with cystatin C vs creatinine: a systematic review","volume":"94","author":"Barreto","year":"2019","journal-title":"Mayo Clin Proceed"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0021","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/aas.12808","article-title":"Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients","volume":"60","author":"Petersson","year":"2016","journal-title":"Acta Anaesthesiologica Scandinavica"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0022","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/jac\/dkac059","article-title":"Population pharmacokinetics of piperacillin\/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation","volume":"77","author":"Kim","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0023","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00228-022-03307-0","article-title":"Estimation of cefepime, piperacillin, and tazobactam clearance with iohexol-based glomerular filtration rate in paediatric patients","volume":"78","author":"Soeorg","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0024","volume":"1","author":"Wilson","year":"2018"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0025","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","article-title":"Reporting Guidelines for Clinical pharmacokinetic studies: the ClinPK Statement","volume":"54","author":"Kanji","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0026","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrneph.2017.2","article-title":"Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup","volume":"13","author":"Chawla","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0027","first-page":"1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"Kellum","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0028","article-title":"Impact of various estimated glomerular filtration rate equations on the pharmacokinetics of meropenem in critically ill adults","volume":"5","author":"Barreto","year":"2023","journal-title":"Crit Care Explor"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0029","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00810-23","article-title":"Population pharmacokinetic model of cefepime for critically ill adults: a comparative assessment of eGFR equations","volume":"67","author":"Barreto","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0030","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/jcph.1773","article-title":"Demonstrating feasibility of an opportunistic sampling approach for pharmacokinetic studies of \u03b2-lactam antibiotics in critically ill children","volume":"61","author":"Tang Girdwood","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0031","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/jalm\/jfab036","article-title":"Stability and validation of a high-throughput LC-MS\/MS method for the quantification of cefepime, meropenem, and piperacillin and tazobactam in serum","volume":"6","author":"Bjergum","year":"2021","journal-title":"J Appl Laborat Med"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0032","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4065\/mcp.2009.0479","article-title":"Informatics infrastructure for syndrome surveillance, decision support, reporting, and modeling of critical illness","volume":"85","author":"Herasevich","year":"2010","journal-title":"Mayo Clin Proceed"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0033","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/01621459.1995.10476572","article-title":"Bayes factors","volume":"90","author":"Kass","year":"1995","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0034","article-title":"Basic concepts in population modeling, simulation, and model-based drug development - part 2: introduction to pharmacokinetic modeling methods","volume":"2","author":"Mould","year":"2013","journal-title":"CPT: Pharmacometrics and Systems Pharmacology"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0035","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10928-019-09633-8","article-title":"Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis","volume":"46","author":"Sukarnjanaset","year":"2019","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0036","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/bcp.14505","article-title":"Estimation of piperacillin clearance with different glomerular filtration rate formulas in critically ill children","volume":"87","author":"B\u00e9ranger","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0037","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/cc13899","article-title":"Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study","volume":"18","author":"Frazee","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0038","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/j.ajkd.2016.11.016","article-title":"Cystatin C-guided vancomycin dosing in critically ill patients: a quality improvement project","volume":"69","author":"Frazee","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0039","doi-asserted-by":"crossref","DOI":"10.1097\/CCM.0000000000006622","article-title":"Cystatin C-guided dosing nomogram improves target attainment for cefepime in the critically ill","author":"Barreto","year":"2025","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0040","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1007\/s00134-022-06921-9","article-title":"Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial","volume":"48","author":"Ewoldt","year":"2022","journal-title":"Intens Care Med"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0041","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00134-021-06609-6","article-title":"Effect of therapeutic drug monitoring-based dose optimization of piperacillin\/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial","volume":"48","author":"Hagel","year":"2022","journal-title":"Intens Care Medicine"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0042","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/CCM.0000000000006237","article-title":"Toward equitable kidney function estimation in Critical Care Practice: guidance from the Society of Critical Care Medicine\u2019s Diversity, Equity, and Inclusion in Renal Clinical Practice Task Force","volume":"52","author":"Miano","year":"2024","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0043","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.34067\/KID.0003202022","article-title":"Advantages, limitations, and clinical considerations in using cystatin C to estimate GFR","volume":"3","author":"Chen","year":"2022","journal-title":"Kidney"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0044","series-title":"Clinical Laboratory Fee Schedule","year":"2025"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0045","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/aas.12629","article-title":"Pharmacokinetics and pharmacodynamics of piperacillin\/tazobactam during high volume haemodiafiltration in patients with septic shock","volume":"60","author":"Tamme","year":"2016","journal-title":"Acta Anaesthesiologica Scandinavica"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0046","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jac\/dkt304","article-title":"Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic\/pharmacodynamic analysis","volume":"69","author":"As\u00edn-Prieto","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0047","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijid.2020.01.010","article-title":"Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy","volume":"92","author":"Bue","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0048","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/cid\/ciaa224","article-title":"The effect of Renal Replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: data from the multinational sampling antibiotics in Renal Replacement Therapy study","volume":"72","author":"Roberts","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0049","article-title":"Antimicrobial exposures in critically ill patients receiving extracorporeal membrane oxygenation","author":"Shekar","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0050","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/jac\/dkab031","article-title":"Impact of extracorporeal membrane oxygenation (ECMO) support on piperacillin exposure in septic patients: a case-control study","volume":"76","author":"Fill\u00e2tre","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107586_bib0051","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01438-21","article-title":"Population pharmacokinetics of piperacillin and Tazobactam in critically ill patients receiving extracorporeal membrane oxygenation: an ASAP ECMO study","volume":"65","author":"Cheng","year":"2021","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925001414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925001414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:34:19Z","timestamp":1789223659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857925001414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0924857925001414"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107586","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Piperacillin\/tazobactam clearance predicted by non-creatinine based estimates of GFR in critically ill adults","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107586"}}